Activities, Bill Numbers and Titles
|
|
Client: The Amyotrophic Lateral Sclerosis Association
|
Total amount paid by client; lobbyist is unable to report compensation at activity level: $7,000.00
|
House Bill
|
1183
|
An Act advancing health care research and decision-making centered on patients and people with disabilities
|
Support
|
$0.00
|
N/A
|
Senate Bill
|
1249
|
An Act relative to reducing administrative burden
|
Support
|
$0.00
|
N/A
|
House Bill
|
2
|
An Act making appropriations for the fiscal year 2025 for the maintenance of the departments, boards, commissions, institutions, and certain activities of the Commonwealth, for interest, sinking fund, and serial bond requirements, and for certain permanent improvements
|
Support
|
$0.00
|
N/A
|
Senate Bill
|
655
|
An Act relative to telehealth and digital equity for patients
|
Support
|
$0.00
|
N/A
|
Senate Bill
|
609
|
An Act relative to consumer deductibles
|
Support
|
$0.00
|
N/A
|
House Bill
|
1074
|
An Act relative to cancer patient access to biomarker testing to provide appropriate therapy
|
Support
|
$0.00
|
N/A
|
House Bill
|
953
|
An Act relative to consumer deductibles
|
Support
|
$0.00
|
N/A
|
House Bill
|
1143
|
An Act to improve the health insurance prior authorization process
|
Support
|
$0.00
|
N/A
|
Senate Bill
|
730
|
An Act advancing health care research and decision-making centered on patients and people with disabilities
|
Support
|
$0.00
|
N/A
|
Senate Bill
|
152
|
An Act expanding wheelchair warranty protections for consumers with disabilities
|
Support
|
$0.00
|
N/A
|
Senate Bill
|
689
|
An Act relative to patient access to biomarker testing to provide appropriate therapy
|
Support
|
$0.00
|
N/A
|
| | |
Total amount
|
$0.00
| |
|
|
|
Meals, Travel, and Entertainment Expenses
|
No meals, travel, or entertainment expenses were filed for this disclosure reporting period. |
|
|
Additional Expenses
|
No additional expenses were filed for this disclosure reporting period. |
|
|
Campaign Contributions
|
No campaign contributions were filed for this disclosure reporting period. |
|